Breast cancer risk models fall short for women with family history, study finds
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 18:16 ET (22-Jun-2026 22:16 GMT/UTC)
A new Cochrane review finds that while some commonly used breast cancer risk models perform reasonably well, none are highly accurate at identifying which women will go on to develop breast cancer.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are disorders associated with dysfunctional lipid metabolism and obesity. In a recent study, researchers have reviewed and compared the definition, causes, diagnostic methods, and emerging treatments of MASLD and IPFD that could help improve patients’ outcomes. In addition, they shed light on recent advances in artificial intelligence applications and presented personalized therapy integrated with the liver‐pancreas axis, providing novel insights for disease management.
The largest real-world study ever conducted on prostate cancer in Brazil analyzed data from 670,205 patients treated through the Brazilian Unified Health System (SUS) over a 16-year period, between 2008 and 2023. Published in the Journal of Global Oncology (JCO), the official journal of the American Society of Clinical Oncology (ASCO), the study included researchers from the D’Or Institute for Research and Education (IDOR) and investigated patterns of diagnosis, treatment, and healthcare costs related to the disease across the country. The results revealed significant racial inequalities, including a higher frequency of advanced disease at diagnosis among non-white men and differences in therapeutic investment.